ArticleDiscover oncology2026
Multi-omic discovery of SCG5 as a shared driver and prognostic biomarker in head-neck and non-small cell lung cancers.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPatients with head and neck squamous cell carcinoma (HNSC) face a high risk of developing non-small cell lung cancer (NSCLC). However, the shared molecular drivers linking these two malignancies remain poorly defined.
methodsWe integrated TCGA and GEO datasets to identify shared differentially expressed genes (DEGs) between HNSC and NSCLC, subsequently evaluating their prognostic value, immune infiltration patterns (ssGSEA), and enriched pathways. Clinical validation of SCG5 protein expression was comprehensively performed using tissue microarrays (TMA) via immunohistochemistry. in vitro assays, including siRNA-mediated knockdown, CCK-8, colony formation, and Western blotting, were conducted in both HNSC (SCC-25) and NSCLC (A549) cell lines to ascertain its oncogenic functions and underlying molecular mechanisms.
resultsSCG5 was identified as a consistently upregulated, independent predictor of poor survival in both cancers. IHC confirmed SCG5 protein overexpression, correlating with lymph node metastasis and advanced clinical stages. GSEA revealed that SCG5-associated genes were significantly enriched in focal adhesion and the PI3K/AKT signaling pathway in both HNSC and NSCLC. SCG5 expression correlated positively with tumor-infiltrating macrophages (P < 0.001) and with PDCD1LG2, HAVCR2 and SIGLEC15 (P < 0.05). SCG5 knockdown significantly suppressed cell proliferation and colony formation in both SCC-25 and A549 cells, concurrently attenuating PI3K and AKT phosphorylation.
conclusionSCG5 is a novel shared oncogenic driver and prognostic biomarker for HNSC and NSCLC. Downregulation of SCG5 suppresses the growth of HNSC and NSCLC cells, potentially through modulating the PI3K/AKT signaling pathway, thereby presenting a potential therapeutic target for both malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.